Table 2.

Patient and tumor characteristics by FISH status

	EGFR FISH (+)		EGFR FISH (−)
	Placebo (n = 57)	Erlotinib (n = 43)	Placebo (n = 67)	Erlotinib (n = 78)
Age (y)
Median	65	67	65	62
Range	40–82	24–81	36–80	35–79
Sex
Male	33 (57.9)	19 (44.2)	41 (61.2)	46 (59.0)
Female	24 (42.1)	24 (55.8)	26 (38.8)	32 (41.0)
Ethnicity
Caucasian	53 (93)	36 (83.7)	64 (95.5)	67 (85.9)
Asian or Pacific Islander	3 (5.3)	1 (2.3)	0 (0.0)	3 (3.8)
Other	1 (1.8)	6 (14.0)	3 (4.5)	8 (10.3)
Smoking history
Never	5 (8.8)	4 (9.3)	2 (3.0)	8 (10.3)
Current	3 (5.3)	7 (16.3)	16 (23.9)	12 (15.4)
Previous	49 (86.0)	32 (74.4)	49 (73.1)	58 (74.4)
Baseline ECOG
0	22 (38.6)	13 (30.2)	21 (31.3)	34 (43.6)
1	35 (61.4)	30 (69.8)	46 (68.7)	44 (56.4)
2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Prior radiotherapy
Yes	12 (21.1)	15 (34.9)	17 (25.4)	17 (21.8)
No	45 (78.9)	28 (65.1)	50 (74.6)	61 (78.2)
Cancer type
Metastatic disease	48 (84.2)	41 (95.3)	57 (85.1)	70 (89.7)
Local advanced disease	9 (15.8)	2 (4.7)	10 (14.9)	8 (10.3)
Months since initial NSCLC diagnosis
<6	47 (82.5)	39 (90.7)	50 (74.6)	67 (85.9)
6–12	4 (7.0)	1 (2.3)	4 (6.0)	2 (2.6)
>12	6 (10.5)	3 (7.0)	13 (19.4)	9 (11.5)
Histology
Squamous cell	7 (12.3)	9 (20.9)	14 (20.9)	16 (20.5)
Adenocarcinoma	40 (70.2)	25 (58.1)	38 (56.7)	43 (55.1)
Large cell	3 (5.3)	3 (7.0)	10 (14.9)	9 (11.5)
Other	7 (12.3)	6 (14.0)	5 (7.5)	10 (12.8)
Weight loss*
Yes	21 (36.8)	13 (30.2)	18 (26.9)	25 (32.1)
No	36 (63.2)	30 (69.8)	49 (73.1)	53 (67.9)
Disease measurability
Measurable	54 (94.7)	30 (90.7)	60 (89.6)	74 (94.9)
Nonmeasurable	3 (5.3)	4 (9.3)	7 (10.4)	4 (5.1)
Cancer stage
IIIB	10 (17.5)	2 (4.7)	10 (14.9)	8 (10.3)
IV	47 (82.5)	41 (95.3)	57 (85.1)	70 (89.7)
EGFR mutation
N	43	32	49	55
Yes	13 (30.2)	11 (34.4)	3 (6.1)	3 (5.5)
No	30 (69.8)	21 (65.6)	46 (93.9)	52 (94.5)
K-ras mutation
n	46	34	55	57
Yes	12 (26.1)	3 (8.8)	12 (21.8)	15 (26.3)
No	34 (73.9)	31 (91.2)	43 (78.2)	42 (73.7)

^*Lost >5 lbs in last 6 mo.